Characterization of the antibody response to pneumococcal glycoconjugates and the effect of heat-labile enterotoxin on IgG subclasses after intranasal immunization

Journal of Infectious Diseases

Volumn 183, Issue 10, 2001, Pages 1494-1500

  Jakobsen, Håvard ^a   Adarna, Brenda C ^a   Schulz, Dominique ^b   Rappuoli, Rino ^c   Jonsdottir, Ingileif ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b SANOFI PASTEUR   (France)

^c CHIRON VACCINES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; PNEUMOCOCCUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; GLYCOCONJUGATES; IMMUNOGLOBULIN G; MICE; MUTATION; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; TETANUS TOXOID;

EID: 0035873750     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/320202     Document Type: Article

References (51)

1. Pneumococcal bacteremia with specific reference to bacteremic pneumococcal pneumonia
2. Preventing pneumococcal diseases in children: Recommendations for using pneumococcal vaccine
3. The microbiology of otitis media
4. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae
5. Natural and vaccine-related immunity to Streptococcus pneumoniae
6. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
7. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations
8. T cell-independent antigens type 2
9. Thymus-independent and thymus-dependent responses to polysaccharide antigens
10. Antibody response to pneumococcal vaccination in children younger than five years of age
11. Human marginal zone B cells
12. Absence of marginal zone B cells in Pyk-2-teficient mice defines their role in the humoral response
13. Immunogenicity of pneumococcal conjugate vaccines
14. Polysaccharide-protein conjugates: A new generation of vaccines
15. Pneumococcal disease: Prospects for a new generation of vaccines
16. Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid
17. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants
18. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
19. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharide conjugated to either tetanus toxoid or diptheria toxoid in young infants and their boosterability by naive polysaccharide antigens
20. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers
21. Subclass restriction of murine anti-carbohydrate antibodies
22. IgG2 subclass restriction of antibody to pneumococcal polysaccharides
23. IgG subclasses in bacterial infections
24. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens
25. Human IgG subclasses and their relation to carbohydrate antigen immunocompetence
26. Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory antipneumococcal antibodies
27. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by experimental pneumococcus type 6B-tetanus toxoid vaccine
28. Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response
29. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies
30. Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic
31. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
32. Genetically derived toxoids for use as vaccines and adjuvants
33. Genetic detoxification of bacterial toxins: A new approach to vaccine development
34. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
35. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant
36. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin
37. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
38. Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: Receptor interaction up-regulates MHC class II, BT, CD40, CD25 and ICAM-1
39. Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4 - dependent or -independent immune responses
40. Mechanisms for mucosal immunogenicity and adjuvanticity of Escherichia coli labile enterotoxin
41. Oral immunization with the B subunit of the heat-labile enterotoxin of Escherichia coli induces early Th1 and late Th2 cytokine expression in Peyer's patches
42. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections
43. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections
44. Functional activity of antibodies elicited by octavalent pneumococcal polysaccharide conjugate vaccines, PncT and PncD
45. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B
46. Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies
47. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes
48. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin
49. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes
50. Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcαRI (CD89)